Pegfilgrastim BS Mochida / Nipro
Pegfilgrastim biosimilar developed by Mochida Pharmaceutical. Reference product Neulasta.
About Pegfilgrastim BS Mochida / Nipro
Pegfilgrastim BS Mochida is the first and only pegfilgrastim biosimilar approved in Japan, in September 2023, also sold under Nipro's name. It is dosed at the Japanese standard of 3.6 mg rather than the 6 mg used elsewhere, against the Japanese reference brand G-Lasta.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Pegfilgrastim BS Mochida / Nipro
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Same developer, other molecules
Other biosimilars in the Atlas developed by Mochida Pharmaceutical: Adalimumab BS MA, Etanercept BS MA, Teriparatide BS Mochida, Tocilizumab BS MA.
Chronology
- PMDASep 2023Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning pegfilgrastim biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant